We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 19, 2022

Aprepitant vs Desloratadine for EGFR-TKI–Induced Pruritus in Patients With NSCLC

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial
Cancer 2022 Oct 05;[EPub Ahead of Print], T Zhou, Y Zhang, Y Ma, W Ma, X Wu, L Huang, W Feng, H Zhou, J Liu, H Zhao, L Zhang, Y Yang, Y Huang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading